Department of Medical Sciences, Rheumatology, Uppsala University, Sweden.
Department of Health Sciences, Luleå University of Technology, Luleå.
Pharmacogenomics. 2020 Apr;21(5):337-346. doi: 10.2217/pgs-2019-0186. Epub 2020 Feb 6.
To investigate whether variants of , and are associated with ALT elevation in rheumatoid arthritis patients starting methotrexate (MTX). Clinical and laboratory data were collected from the start of MTX treatment. Genotyping of , and was performed. Univariate and multiple logistic regression were used for statistical analysis. 34 out of 369 patients experienced ALT >1.5 × ULN less than 6 months from start. A1298C (rs1801131) was nominally associated with an ALT >1.5 × ULN within 6 months after the start of MTX (OR = 1.7 [95% CI: 1.04-2.9]; p = 0.03), but did not pass correction for multiple testing. A multiple model containing 1298C and clinical factors predicted the outcome (C-statistic 0.735). and were not associated with the outcome. A model containing 1298C and clinical factors might predict risk of early ALT elevation.
为了研究 、 和 中的变异是否与开始使用甲氨蝶呤 (MTX) 的类风湿关节炎患者的 ALT 升高有关。从 MTX 治疗开始时收集临床和实验室数据。对 、 和 进行基因分型。采用单变量和多变量逻辑回归进行统计分析。在开始 MTX 治疗不到 6 个月的 369 名患者中有 34 名出现 ALT>1.5×ULN。A1298C(rs1801131)在 MTX 开始后 6 个月内与 ALT>1.5×ULN 呈名义相关（OR=1.7[95%CI:1.04-2.9];p=0.03），但未通过多重检验校正。包含 1298C 和临床因素的多模型预测了结果（C 统计量 0.735）。和 与结果无关。包含 1298C 和临床因素的模型可能预测早期 ALT 升高的风险。
